Fig. 8From: Is triple antithrombotic therapy a safe option in patients with AF who receive drug-eluting stents?: a review articleENTRUST-AF-PCI (2019) trial: Primary outcomes of major bleeding were significantly high in the TAT group compared to both DAT (edoxapan 60Â mg). dabi. *failed to show any superiority but only non-inferiority [24]. DOI: https://doi.org/10.1016/S0140-6736(19)31872-0Back to article page